{
    "clinical_study": {
        "@rank": "153116", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease\n      subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will\n      also be evaluated."
        }, 
        "brief_title": "Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects with a diagnosis of idiopathic Parkinson's disease.\n\n          -  Daily L-dopa dose between 300 and 1200 mg.\n\n          -  MBRS score >1.\n\n        Exclusion Criteria:\n\n          -  Surgical intervention for Parkinson's disease.\n\n          -  History of troublesome dyskinesias.\n\n          -  Any significant AXIS I psychiatric disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02006290", 
            "org_study_id": "B7441003"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "single oral split dose 30+20 mg QD", 
                "intervention_name": "PF-06412562", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "tablet, matching placebo, QD", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 21, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7441003&StudyName=Efficacy%2C%20Safety%20And%20Tolerability%20Study%20In%20Subjects%20With%20Parkinson%u2019s%20Disease"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aventura", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33180"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baco Raton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33486"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bingham Farms", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48025"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27612"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "maximum percent improvement from baseline in finger tapping speed as measured by the Kinesia Technology", 
            "measure": "Finger tapping speed", 
            "safety_issue": "No", 
            "time_frame": "12 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02006290"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "Yes", 
                "time_frame": "0, 0.5, 1, 2, 4, 5,8,12, 24 hours"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 0, 0.5, 1, 2, 4, 8, 12, 24 hours"
            }, 
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 0, 0.5, 1, 2, 4, 8, 12, 24 hours"
            }, 
            {
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 0, 0.5, 1, 2, 4, 8, 12, 24 hours"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 8, 12, 24 hours"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 8, 12, 24 hours"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Mean Residence Time (MRT)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 8, 12, 24 hours"
            }, 
            {
                "description": "C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of \"Yes\" on \"actual attempt\"), preparatory acts toward imminent suicidal behavior (3)(\"Yes\" on \"preparatory acts or behavior\"), suicidal ideation (4) (\"Yes\" on \"wish to be dead\", \"non-specific active suicidal thoughts\", \"active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)(\"Yes\" on \"Has subject engaged in non-suicidal self-injurious behavior\").", 
                "measure": "Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}